• +1-646-491-9876
    • +91-20-67278686

    Search

    Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2017

    Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2017

    • Report Code ID: RW0001709463
    • Category Pharmaceuticals
    • No. of Pages 193
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.

    H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs) .

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 8, 7, 1, 41 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 11 and 3 molecules, respectively.

    Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 7
    Introduction 8
    Publisher Report Coverage 8
    Influenza A Virus, H1N1 Subtype Infections - Overview 9
    Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development 10
    Pipeline Overview 10
    Pipeline by Companies 11
    Pipeline by Universities/Institutes 15
    Products under Development by Companies 17
    Products under Development by Universities/Institutes 22
    Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment 23
    Assessment by Target 23
    Assessment by Mechanism of Action 25
    Assessment by Route of Administration 27
    Assessment by Molecule Type 29
    Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development 31
    AbbVie Inc 31
    Akshaya Bio Inc 31
    Altimmune Inc 32
    Antigen Express Inc 32
    Beijing Minhai Biotechnology Co Ltd 33
    CEL-SCI Corp 33
    Cilian AG 34
    Cocrystal Pharma Inc 34
    ContraFect Corp 35
    Curevac AG 35
    EpiVax Inc 36
    Etubics Corp 36
    Gemmus Pharma Inc 37
    Genentech Inc 37
    iBio Inc 38
    ILiAD Biotechnologies LLC 38
    Inovio Pharmaceuticals Inc 39
    Johnson & Johnson 39
    Kineta Inc 40
    Kyowa Hakko Kirin Co Ltd 40
    Lakewood-Amedex Inc 41
    Medicago Inc 41
    MedImmune LLC 42
    Microbiotix Inc 42
    Mucosis BV 43
    NanoViricides Inc 43
    NewLink Genetics Corp 44
    Novavax Inc 44
    OPKO Health Inc 45
    PeptiDream Inc 45
    Prommune Inc 46
    Protein Sciences Corp 46
    Recce Ltd 47
    Sanofi Pasteur SA 47
    Sarepta Therapeutics Inc 48
    SK Chemicals Co Ltd 48
    Takeda Pharmaceutical Company Ltd 49
    TechnoVax Inc 49
    Touchlight Genetics Ltd 50
    Vaccibody AS 50
    Vaxart Inc 51
    Vironova AB 51
    Visterra Inc 51
    Zydus Cadila Healthcare Ltd 52
    Influenza A Virus, H1N1 Subtype Infections - Drug Profiles 53
    AE-AI vaccine - Drug Profile 53
    AEA-35p - Drug Profile 54
    Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza A Virus, H1N1 Subtype Infections - Drug Profile 55
    Aspidasept - Drug Profile 56
    AV-5027 - Drug Profile 57
    AV-5080 - Drug Profile 58
    CC-42344 - Drug Profile 59
    cetylpyridinium chloride - Drug Profile 60
    CF-401 - Drug Profile 61
    CHOS-05 - Drug Profile 62
    CiFlu - Drug Profile 63
    diridavumab - Drug Profile 65
    EP-67 - Drug Profile 67
    ETBX-051 - Drug Profile 68
    Flu-v - Drug Profile 69
    Fluad (quadrivalent) - Drug Profile 71
    Fludase - Drug Profile 72
    FluGEM - Drug Profile 75
    Gamma-Flu - Drug Profile 76
    GP-1001 - Drug Profile 77
    GP-1681 - Drug Profile 78
    GREFLU/CAL - Drug Profile 80
    H1N1 [A/Aichi/2/68] vaccine - Drug Profile 81
    HB-36.6 - Drug Profile 82
    IN-1 - Drug Profile 83
    infectious disease vaccine - Drug Profile 84
    Influ-nRNA - Drug Profile 85
    influenza [strain A/H1N1] vaccine - Drug Profile 86
    influenza [strain A/H1N1] vaccine - Drug Profile 88
    influenza [strain A/H1N1] vaccine - Drug Profile 89
    influenza [strain H1N1] (virus like particle) vaccine - Drug Profile 90
    influenza [strain H1N1] vaccine - Drug Profile 91
    influenza [strain H1N1] vaccine - Drug Profile 92
    influenza [strain H1N1] vaccine - Drug Profile 93
    influenza [strain H1N1] vaccine - Drug Profile 94
    influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 95
    influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 96
    influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 97
    influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 98
    influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile 99
    influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 102
    influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 103
    influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 104
    influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile 105
    influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 109
    influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 110
    influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 111
    influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile 112
    influenza [strains A/H1N1 + A/H5N1] vaccine - Drug Profile 113
    influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile 114
    influenza vaccine - Drug Profile 115
    INO-3510 - Drug Profile 116
    JNJ-3872 - Drug Profile 118
    KIN-1148 - Drug Profile 121
    KIN-1400 - Drug Profile 123
    LEAPS-H1N1-DC - Drug Profile 125
    MBX-2329 - Drug Profile 126
    MBX-2546 - Drug Profile 127
    Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections - Drug Profile 128
    Nasovax - Drug Profile 129
    NBP-607 - Drug Profile 131
    NEO-8877 - Drug Profile 132
    Nucleozin - Drug Profile 133
    NVINF-1 - Drug Profile 134
    NVINF-2 - Drug Profile 139
    Oligonucleotide to Activate RIG-1 for Influenza A Virus H1N1 Infections - Drug Profile 142
    PD-001 - Drug Profile 143
    Peptides for Influenza Infections - Drug Profile 144
    pertussis [strain BPZE1] vaccine - Drug Profile 145
    PNSIA-28 - Drug Profile 147
    PNSIA-49 - Drug Profile 148
    radavirsen - Drug Profile 149
    RECCE-327 - Drug Profile 151
    RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection - Drug Profile 153
    Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile 154
    Small Molecules for RSV and Influenza A Infections - Drug Profile 155
    Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile 156
    Small Molecules to Inhibit Influenza A Endonuclease for H1N1 Infections - Drug Profile 157
    Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 158
    TVX-002 - Drug Profile 159
    VH-244 - Drug Profile 160
    VIS-410 - Drug Profile 161
    VNFC-045 - Drug Profile 164
    VNFC-051 - Drug Profile 165
    VXAA-1.1 - Drug Profile 166
    WLBU-2 - Drug Profile 168
    Z-3G1 - Drug Profile 169
    Influenza A Virus, H1N1 Subtype Infections - Dormant Projects 170
    Influenza A Virus, H1N1 Subtype Infections - Discontinued Products 173
    Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones 174
    Featured News & Press Releases 174
    Appendix 186
    Methodology 186
    Coverage 186
    Secondary Research 186
    Primary Research 186
    Expert Panel Validation 186
    Contact Us 186
    Disclaimer 187

    List of Tables

    Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by AbbVie Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Altimmune Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Antigen Express Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by CEL-SCI Corp, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cilian AG, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by ContraFect Corp, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Curevac AG, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by EpiVax Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Etubics Corp, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Gemmus Pharma Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Genentech Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by iBio Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by ILiAD Biotechnologies LLC, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Johnson & Johnson, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kineta Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Lakewood-Amedex Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Medicago Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by MedImmune LLC, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Microbiotix Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Mucosis BV, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by NanoViricides Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by NewLink Genetics Corp, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Novavax Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by OPKO Health Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by PeptiDream Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Prommune Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Protein Sciences Corp, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Recce Ltd, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sanofi Pasteur SA, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by SK Chemicals Co Ltd, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by TechnoVax Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Touchlight Genetics Ltd, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaccibody AS, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaxart Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vironova AB, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Visterra Inc, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Influenza A Virus, H1N1 Subtype Infections - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    AbbVie Inc
    Akshaya Bio Inc
    Altimmune Inc
    Antigen Express Inc
    Beijing Minhai Biotechnology Co Ltd
    CEL-SCI Corp
    Cilian AG
    Cocrystal Pharma Inc
    ContraFect Corp
    Curevac AG
    EpiVax Inc
    Etubics Corp
    Gemmus Pharma Inc
    Genentech Inc
    iBio Inc
    ILiAD Biotechnologies LLC
    Inovio Pharmaceuticals Inc
    Johnson & Johnson
    Kineta Inc
    Kyowa Hakko Kirin Co Ltd
    Lakewood-Amedex Inc
    Medicago Inc
    MedImmune LLC
    Microbiotix Inc
    Mucosis BV
    NanoViricides Inc
    NewLink Genetics Corp
    Novavax Inc
    OPKO Health Inc
    PeptiDream Inc
    Prommune Inc
    Protein Sciences Corp
    Recce Ltd
    Sanofi Pasteur SA
    Sarepta Therapeutics Inc
    SK Chemicals Co Ltd
    Takeda Pharmaceutical Company Ltd
    TechnoVax Inc
    Touchlight Genetics Ltd
    Vaccibody AS
    Vaxart Inc
    Vironova AB
    Visterra Inc
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//influenza-a-virus-h1n1-subtype-infections-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//influenza-a-virus-h1n1-subtype-infections-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//influenza-a-virus-h1n1-subtype-infections-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments